LOGIN  |  REGISTER
Terns Pharmaceuticals

Acadia Healthcare to Present at the 41st Annual J.P. Morgan Healthcare Conference

January 04, 2023 | Last Trade: US$14.49 0.21 -1.43

Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that the Company will present at the 41st Annual J.P. Morgan Healthcare Conference, January 9-12, 2023, at The Westin St. Francis, San Francisco, California. In connection with the conference, there will be a webcast of the Company’s presentation available on the Company’s website starting at 2:15 p.m. Pacific Time/4:15 p.m. Central Time on Tuesday, January 10, 2023.

The live webcast of the presentation will be available on the Company’s website, www.acadiahealthcare.com, by clicking on the “Investor Relations” link. A replay of the presentation will also be available on the Company’s website for thirty days.

About Acadia Healthcare

Acadia is a leading provider of behavioral healthcare services across the United States. As of November 30, 2022, Acadia operated a network of 246 behavioral healthcare facilities with approximately 10,800 beds in 39 states and Puerto Rico. With more than 22,500 employees serving approximately 75,000 patients daily, Acadia is the largest stand-alone behavioral healthcare company in the U.S. Acadia provides behavioral healthcare services to its patients in a variety of settings, including inpatient psychiatric hospitals, specialty treatment facilities, residential treatment centers and outpatient clinics.

C4 Therapeutics

Stock Quote

Featured Stock

Amneal Pharmaceuticals

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page